210 related articles for article (PubMed ID: 23299391)
1. Preclinical antitumor activity of a nanoparticulate SN38.
Al-Kasspooles MF; Williamson SK; Henry D; Howell J; Niu F; Decedue CJ; Roby KF
Invest New Drugs; 2013 Aug; 31(4):871-80. PubMed ID: 23299391
[TBL] [Abstract][Full Text] [Related]
2. Single protein encapsulated SN38 for tumor-targeting treatment.
Yu C; Huang F; Wang K; Liu M; Chow WA; Ling X; Li F; Causey JL; Huang X; Cook-Wiens G; Cui X
J Transl Med; 2023 Dec; 21(1):897. PubMed ID: 38072965
[TBL] [Abstract][Full Text] [Related]
3. SN38 polymeric nanoparticles: in vitro cytotoxicity and in vivo antitumor efficacy in xenograft balb/c model with breast cancer versus irinotecan.
Sepehri N; Rouhani H; Tavassolian F; Montazeri H; Khoshayand MR; Ghahremani MH; Ostad SN; Atyabi F; Dinarvand R
Int J Pharm; 2014 Aug; 471(1-2):485-97. PubMed ID: 24879937
[TBL] [Abstract][Full Text] [Related]
4. The histone deacetylase inhibitor PXD101 increases the efficacy of irinotecan in in vitro and in vivo colon cancer models.
Na YS; Jung KA; Kim SM; Hong YS; Ryu MH; Jang SJ; Moon DH; Cho DH; Kim JC; Lee JS; Kim TW
Cancer Chemother Pharmacol; 2011 Aug; 68(2):389-98. PubMed ID: 21046105
[TBL] [Abstract][Full Text] [Related]
5. Nanoparticle delivery of an SN38 conjugate is more effective than irinotecan in a mouse model of neuroblastoma.
Iyer R; Croucher JL; Chorny M; Mangino JL; Alferiev IS; Levy RJ; Kolla V; Brodeur GM
Cancer Lett; 2015 May; 360(2):205-12. PubMed ID: 25684664
[TBL] [Abstract][Full Text] [Related]
6. Targeting the p38 MAPK pathway inhibits irinotecan resistance in colon adenocarcinoma.
Paillas S; Boissière F; Bibeau F; Denouel A; Mollevi C; Causse A; Denis V; Vezzio-Vié N; Marzi L; Cortijo C; Ait-Arsa I; Askari N; Pourquier P; Martineau P; Del Rio M; Gongora C
Cancer Res; 2011 Feb; 71(3):1041-9. PubMed ID: 21159664
[TBL] [Abstract][Full Text] [Related]
7. Lipid nanoparticles loaded with 7-ethyl-10-hydroxycamptothecin-phospholipid complex: in vitro and in vivo studies.
Liu H; Lu H; Liao L; Zhang X; Gong T; Zhang Z
Drug Deliv; 2015; 22(6):701-9. PubMed ID: 24625262
[TBL] [Abstract][Full Text] [Related]
8. DTS-108, a novel peptidic prodrug of SN38: in vivo efficacy and toxicokinetic studies.
Meyer-Losic F; Nicolazzi C; Quinonero J; Ribes F; Michel M; Dubois V; de Coupade C; Boukaissi M; Chéné AS; Tranchant I; Arranz V; Zoubaa I; Fruchart JS; Ravel D; Kearsey J
Clin Cancer Res; 2008 Apr; 14(7):2145-53. PubMed ID: 18381956
[TBL] [Abstract][Full Text] [Related]
9. A nanotherapeutic strategy to overcome chemoresistance to irinotecan/7-ethyl-10-hydroxy-camptothecin in colorectal cancer.
Huang Q; Liu X; Wang H; Liu X; Zhang Q; Li K; Chen Y; Zhu Q; Shen Y; Sui M
Acta Biomater; 2022 Jan; 137():262-275. PubMed ID: 34718178
[TBL] [Abstract][Full Text] [Related]
10. Tissue penetration and activity of camptothecins in solid tumor xenografts.
Kyle AH; Baker JH; Gandolfo MJ; Reinsberg SA; Minchinton AI
Mol Cancer Ther; 2014 Nov; 13(11):2727-37. PubMed ID: 25143448
[TBL] [Abstract][Full Text] [Related]
11. Development and pharmacological evaluation of a PEG based nanoparticulate camptothecin analog for oral administration.
Nekkanti V; Venkateswarlu V; Ansari KA; Pillai R
Curr Drug Deliv; 2011 Nov; 8(6):661-6. PubMed ID: 22313161
[TBL] [Abstract][Full Text] [Related]
12. Novel lipophilic SN38 prodrug forming stable liposomes for colorectal carcinoma therapy.
Xing J; Zhang X; Wang Z; Zhang H; Chen P; Zhou G; Sun C; Gu N; Ji M
Int J Nanomedicine; 2019; 14():5201-5213. PubMed ID: 31371956
[No Abstract] [Full Text] [Related]
13. An EGFR inhibitor enhances the efficacy of SN38, an active metabolite of irinotecan, in SN38-refractory gastric carcinoma cells.
Yashiro M; Qiu H; Hasegawa T; Zhang X; Matsuzaki T; Hirakawa K
Br J Cancer; 2011 Nov; 105(10):1522-32. PubMed ID: 21997136
[TBL] [Abstract][Full Text] [Related]
14. Synthesis, characterization, and antitumor evaluation of the albumin-SN38 conjugate.
Yao Y; Su X; Xie Y; Wang Y; Kang T; Gou L; Yi C; Yang J
Anticancer Drugs; 2013 Mar; 24(3):270-7. PubMed ID: 23233044
[TBL] [Abstract][Full Text] [Related]
15. Pharmacogenomic profiling and pathway analyses identify MAPK-dependent migration as an acute response to SN38 in p53 null and p53-mutant colorectal cancer cells.
Allen WL; Turkington RC; Stevenson L; Carson G; Coyle VM; Hector S; Dunne P; Van Schaeybroeck S; Longley DB; Johnston PG
Mol Cancer Ther; 2012 Aug; 11(8):1724-34. PubMed ID: 22665525
[TBL] [Abstract][Full Text] [Related]
16. Irinotecan metabolite SN38 results in germ cell loss in the testis but not in the ovary of prepubertal mice.
Lopes F; Smith R; Nash S; Mitchell RT; Spears N
Mol Hum Reprod; 2016 Nov; 22(11):745-755. PubMed ID: 27470502
[TBL] [Abstract][Full Text] [Related]
17. Altered expression of cell proliferation-related and interferon-stimulated genes in colon cancer cells resistant to SN38.
Gongora C; Candeil L; Vezzio N; Copois V; Denis V; Breil C; Molina F; Fraslon C; Conseiller E; Pau B; Martineau P; Del Rio M
Cancer Biol Ther; 2008 Jun; 7(6):822-32. PubMed ID: 18340113
[TBL] [Abstract][Full Text] [Related]
18. Synthesis, characterization, and evaluation of mPEG-SN38 and mPEG-PLA-SN38 micelles for cancer therapy.
Xie J; Zhang X; Teng M; Yu B; Yang S; Lee RJ; Teng L
Int J Nanomedicine; 2016; 11():1677-86. PubMed ID: 27217746
[TBL] [Abstract][Full Text] [Related]
19. [Irinotecan pharmacokinetics].
Chabot GG; Robert J; Lokiec F; Canal P
Bull Cancer; 1998 Dec; Spec No():11-20. PubMed ID: 9932079
[TBL] [Abstract][Full Text] [Related]
20. Pregnane X Receptor (PXR) expression in colorectal cancer cells restricts irinotecan chemosensitivity through enhanced SN-38 glucuronidation.
Raynal C; Pascussi JM; Leguelinel G; Breuker C; Kantar J; Lallemant B; Poujol S; Bonnans C; Joubert D; Hollande F; Lumbroso S; Brouillet JP; Evrard A
Mol Cancer; 2010 Mar; 9():46. PubMed ID: 20196838
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]